FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4232800613> ?p ?o ?g. }

• W4232800613 endingPage "3059" @default.
• W4232800613 startingPage "3059" @default.
• W4232800613 abstract "Abstract Allogeneic hematopoietic cell transplantation (HCT) using reduced intensity conditioning (RIC) regimens offers a potential curative therapy to patients with advanced NHL. RIC HCT induces potent graft-versus-lymphoma effects with best results in patients with low tumor burden at time of HCT. Combined use of radioimmunotherapy (RIT) with RIC may increase anti-lymphoma activity of RIC while HCT provides rescue from hematologic toxicity of RIT. This may allow dose escalation of RIT. A multicenter phase I/II study of allogeneic HCT combining RIT using yttrium-90-ibritumomab tiuxetan (Y90-CD20) with two RIC regimens for treatment of patients with NHL has been initiated. Patients with indolent NHL (Arm A) receive RIT with Y90-CD20 (0.4 mCi/kg) on day −14 combined with RIC using fludarabine (30 mg/m^2 day −4 to−2) and 2 Gy TBI (day 0). Patients with aggressive NHL (Arm B) receive an escalated dose of Y90-CD20 (0,6–0,8 mCi/kg) on day −14 combined with RIC using fludarabine (30 mg/m^2 day −8 to−4), melphalan (140 mg/m^2 day −3) and campath (20–30 mg day −3 to−2). For postgrafting immunosuppression either CSA/MMF (Arm A) or CSA alone (Arm B) is used. To date, 31 patients have been enrolled (Arm A=23, Arm B=8). Diagnoses in Arm A were FL (n=12), MCL (n=6), CLL (n=4) and Immunocytoma (n=1). Diagnoses in Arm B were DLBCL (n=6), blastoid MCL (n=1) and transformed CLL (n=1). Median age was 55 (range, 34–67) years. PBSC grafts were either from matched related (n=10) or matched unrelated donors (n=21). All patients were high risk with refractory disease or relapse after preceding HCT. Disease status after salvage therapy at time of HCT was in Arm A: CR=1, PR=18, SD=4 and in Arm B: PR=8. No additional toxicity due to RIT was observed. Engraftment was rapid and sustained with no graft rejections. In Arm A median time to >500 granulocytes/μL was 13 (range, 0–69) days and to >20000 platelets/μL 3 (range, 0–69) days (in 11 patients platelets never dropped <20000/μL). In Arm B median time to >500 granulocytes/μL was 17 (range, 9–23) days and to >20000 platelets/μL 11 (range, 8–29) days. TRM in the first 100 days was 3%, overall 19%. Incidence of grade II-IV GVHD in Arm A was 35% (II=3, III=4, IV=1) and in Arm B 25% (II=2). Best disease response observed was in Arm A: CR=18, PR=5 and in Arm B: CR=3, PR=5. To date, 16/23 patients in Arm A and 6/8 patients in Arm B are alive with a median follow-up of 271 (range, 20–390) days, resulting in a Kaplan-Meier 1 year survival estimate of 65% in Arm A and 62% in Arm B. Causes of death were infection=5, GVHD=1, relapse=1 in Arm A and relapse=2 in Arm B. A combination of RIT with RIC is feasible with no additional toxicity due to RIT and stable engraftment in all patients. Preliminary response data suggest that this strategy may improve early post-transplant disease control, but long-term disease-free survival remains to be determined." @default.
• W4232800613 created "2022-05-12" @default.
• W4232800613 creator A5001361845 @default.
• W4232800613 creator A5002578778 @default.
• W4232800613 creator A5005122036 @default.
• W4232800613 creator A5017987266 @default.
• W4232800613 creator A5023183268 @default.
• W4232800613 creator A5026611811 @default.
• W4232800613 creator A5040594919 @default.
• W4232800613 creator A5042854645 @default.
• W4232800613 creator A5047060286 @default.
• W4232800613 creator A5055821837 @default.
• W4232800613 creator A5066624700 @default.
• W4232800613 creator A5086135617 @default.
• W4232800613 date "2007-11-16" @default.
• W4232800613 modified "2023-09-28" @default.
• W4232800613 title "Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Non-Hodgkin Lymphoma: A Phase I/II Study." @default.
• W4232800613 doi "https://doi.org/10.1182/blood.v110.11.3059.3059" @default.
• W4232800613 hasPublicationYear "2007" @default.
• W4232800613 type Work @default.
• W4232800613 citedByCount "1" @default.
• W4232800613 crossrefType "journal-article" @default.
• W4232800613 hasAuthorship W4232800613A5001361845 @default.
• W4232800613 hasAuthorship W4232800613A5002578778 @default.
• W4232800613 hasAuthorship W4232800613A5005122036 @default.
• W4232800613 hasAuthorship W4232800613A5017987266 @default.
• W4232800613 hasAuthorship W4232800613A5023183268 @default.
• W4232800613 hasAuthorship W4232800613A5026611811 @default.
• W4232800613 hasAuthorship W4232800613A5040594919 @default.
• W4232800613 hasAuthorship W4232800613A5042854645 @default.
• W4232800613 hasAuthorship W4232800613A5047060286 @default.
• W4232800613 hasAuthorship W4232800613A5055821837 @default.
• W4232800613 hasAuthorship W4232800613A5066624700 @default.
• W4232800613 hasAuthorship W4232800613A5086135617 @default.
• W4232800613 hasConcept C126322002 @default.
• W4232800613 hasConcept C141071460 @default.
• W4232800613 hasConcept C143998085 @default.
• W4232800613 hasConcept C159654299 @default.
• W4232800613 hasConcept C203014093 @default.
• W4232800613 hasConcept C2776146153 @default.
• W4232800613 hasConcept C2776694085 @default.
• W4232800613 hasConcept C2776755627 @default.
• W4232800613 hasConcept C2778515704 @default.
• W4232800613 hasConcept C2778559949 @default.
• W4232800613 hasConcept C2778684742 @default.
• W4232800613 hasConcept C2779263901 @default.
• W4232800613 hasConcept C2779338263 @default.
• W4232800613 hasConcept C2781413609 @default.
• W4232800613 hasConcept C2911091166 @default.
• W4232800613 hasConcept C542903549 @default.
• W4232800613 hasConcept C71924100 @default.
• W4232800613 hasConcept C90924648 @default.
• W4232800613 hasConceptScore W4232800613C126322002 @default.
• W4232800613 hasConceptScore W4232800613C141071460 @default.
• W4232800613 hasConceptScore W4232800613C143998085 @default.
• W4232800613 hasConceptScore W4232800613C159654299 @default.
• W4232800613 hasConceptScore W4232800613C203014093 @default.
• W4232800613 hasConceptScore W4232800613C2776146153 @default.
• W4232800613 hasConceptScore W4232800613C2776694085 @default.
• W4232800613 hasConceptScore W4232800613C2776755627 @default.
• W4232800613 hasConceptScore W4232800613C2778515704 @default.
• W4232800613 hasConceptScore W4232800613C2778559949 @default.
• W4232800613 hasConceptScore W4232800613C2778684742 @default.
• W4232800613 hasConceptScore W4232800613C2779263901 @default.
• W4232800613 hasConceptScore W4232800613C2779338263 @default.
• W4232800613 hasConceptScore W4232800613C2781413609 @default.
• W4232800613 hasConceptScore W4232800613C2911091166 @default.
• W4232800613 hasConceptScore W4232800613C542903549 @default.
• W4232800613 hasConceptScore W4232800613C71924100 @default.
• W4232800613 hasConceptScore W4232800613C90924648 @default.
• W4232800613 hasIssue "11" @default.
• W4232800613 hasLocation W42328006131 @default.
• W4232800613 hasOpenAccess W4232800613 @default.
• W4232800613 hasPrimaryLocation W42328006131 @default.
• W4232800613 hasRelatedWork W1977240833 @default.
• W4232800613 hasRelatedWork W2024629263 @default.
• W4232800613 hasRelatedWork W2045476729 @default.
• W4232800613 hasRelatedWork W2068795972 @default.
• W4232800613 hasRelatedWork W2553142552 @default.
• W4232800613 hasRelatedWork W2594364505 @default.
• W4232800613 hasRelatedWork W2599310198 @default.
• W4232800613 hasRelatedWork W2606888082 @default.
• W4232800613 hasRelatedWork W2980938688 @default.
• W4232800613 hasRelatedWork W4232800613 @default.
• W4232800613 hasVolume "110" @default.
• W4232800613 isParatext "false" @default.
• W4232800613 isRetracted "false" @default.
• W4232800613 workType "article" @default.